[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esophagogastric-junction-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esophagogastric-junction-cancer":92},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,73],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100425577",false,"NCT04821778","Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer","Cohort Study of Definitive Chemoradiotherapy for Esophageal or Esophagogastric Junction Cancer","Inclusion Criteria:\n\n* ≥18 years；\n* Esophageal or Esophagogastric cancer；\n* Histologically proven squamous cell carcinoma or adenocarcinoma in patients staged as I-IVa(AJCC 8th)；\n* Primary treatment performed in Cancer Hospital, Chinese Academy of Medical Sciences；\n* ECOG PS score: 0\\~1；\n* Estimated survival time ≥3 months；\n* Normal organ and marrow function as defined below:Hemoglobin: greater than or equal to 100g\u002FL ;Leukocytes: greater than or equal to 4,000 G\u002FL; Neutrophil: greater than or equal to 2,000 G\u002FL; Platelets: greater than or equal to 100,000\u002Fmm3 ; Creatinine: less than or equal to 1.5 times the upper limit or CCR greater than or equal to 60 ml\u002Fmin; AST\u002FALT: less than or equal to 2.5 times the upper limit; Total bilirubin: less than or equal to 1.5 times the upper limit; INR: less than or equal to 1.5 times the upper limit; APTT: less than or equal to 1.5 times the upper limit; PT: less than or equal to 1.5 times the upper limit；\n* Informed consent；\n\nExclusion Criteria:\n\n* With any distant metastasis out of regional lymphatic drainage or in liver, lung, bone, CNS, etc；\n* Patients with other cancer history in 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer；\n* Existing active infection such as active tuberculosis and hepatitis；\n* History of myocardial infarction within the past 6 months or history of ventricular arrhythmia；\n* Uncontrolled illness including, but not limited to, active infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness History of allergic reactions attributed to paclitaxel, albumin or cisplatin；\n* Participation in other clinical trials currently or within 4 weeks of selection；\n* Pregnant or lactating females；\n* Absence of medical records.","ALL","18 Years",{"count":18,"type":19},2000,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","Definitive chemoradiotherapy is the standard of care in unresectable esophageal or esophagogastric cancer. A multidisciplinary approach, including chemotherapy and radiotherapy, is important for these patients. Morerover, molecular targeting agents does not show clear efficacy in EC up to now. Nowadays, the pace of development of cancer immunotherapies is accelerating. Clinical evidence of the efficacy of immune checkpoint inhibitors and adoptive immunotherapies herald the onset of a new era in cancer immunotherapy. There have also been recent developments to provide a promising frontier in extending the use of immunotherpay or targeting agents to radiotherapy. The purpose of this study was to explore the optimal treatment modalities including PD-1\u002FPD-L1 antibody or targeted drug for patients with unresectable esophageal or esophagogastric junction cancer.",[25,26,27,28,29,30],"Esophagus Cancer","Esophagogastric Junction Cancer","Chemoradiation","Targeted Therapy","Immunotherapy","Chemotherapy Effect","RECRUITING","2026-01-18",{"date":34,"type":35},"2026-01-21","ACTUAL",{"date":37,"type":35},"2002-01-01",{"date":39,"type":19},"2030-12-31",{"name":41,"class":42},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",5,{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100539948","NCT06310473","Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial","Efficacy and Safety of Neoadjuvant Cadonilimab and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer : a Prospective, Open-label, Single-Arm Phase II Study","Key Inclusion Criteria:\n\n1. Confirmed gastric and gastroesophageal junction adenocarcinoma by Gastroscopic biopsy histopathological examination.\n2. Imaging (CT\u002FMRI) and diagnostic laparoscopy confirmed at the stage of cT3-4aN1-3M0(AJCC 8th) .\n3. Physical condition and organ function allow for for larger abdominal surgery.\n4. Adequate haematological, renal and liver function.\n\nKey Exclusion Criteria:\n\n1. Patients who have HER2 positive confiemed with IHC3+ or IHC2+ and FISH positive.\n2. Confirmed at stage IV (AJCC 8th) or unresectable by investigator.\n3. Prior chemotherapy, radiotherapy, surgery immunotherapy or molecular targeted therapy for gastric cancer.\n4. Patients are allergic to study medication and its ingredients.\n5. Known active autoimmune diseases.\n6. Presence of other uncontrolled serious medical conditions.","75 Years",{"count":52,"type":19},30,[54],"PHASE2","For locally advanced esophagogastric junction and gastric cancer, neoadjuvant chemotherapy can downstage T and N stage,treated distant micrometastases early , and finally improve the long-term survival. Combination of perioperative PD-1 antibody and chemotherapy for locally advanced esophagogastric junction and gastric cancer could be a novel therapy to increase response rate and reduce recurrence rate.Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer.",[57,26],"Gastric Cancer",[59,60,61],"bispecific antibody","Neoadjuvant","Immunotherapy and Chemotherapy","NOT_YET_RECRUITING","2024-03-07",{"date":65,"type":35},"2024-03-15",{"date":67,"type":19},"2024-03",{"date":69,"type":19},"2028-03",{"name":71,"class":42},"Nanfang Hospital, Southern Medical University",1,{"id":74,"slug":4,"hasResults":10,"nctId":75,"briefTitle":76,"officialTitle":4,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":20,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":72},"100284924","NCT02988921","MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy","Inclusion Criteria:\n\n* Histologically confirmed squamous cell carcinoma, adenocarcinoma of the esophageal or esophagogastric junction\n* Unresectable or potentially resectable tumor (cT3-4N0-1M0-M1a, according to AJCC 6th) based on standard primary staging by EUS and CT\n* Age\\>18 years\n* No distant metastasis other than supraclavicular lymph nodes\n* No prior history of thoracic radiation or chemotherapy\n* Patients must have normal organ and marrow function as defined below: Leukocytes: greater than or equal to 3,500 G\u002FL; Platelets: greater than or equal to 100,000\u002Fmm3 .Hemoglobin:greater than or equal to 10g\u002FL .Total bilirubin: within normal institutional limits; AST\u002FALT: less than or equal to 1.5 times the upper limit; Creatinine within normal upper limits\n* Informed consent\n\nExclusion Criteria:\n\n* Contraindication for MRI scanning\n* Patients with other cancer history except cervical carcinoma in situ and non-malignant melanoma skin cancer\n* Pregnant or lactating females\n* Contraindication for radiotherapy or chemotherapy",{"count":79,"type":19},300,[81],"NA","Magnetic resonance imaging (MRI) with functional features of diffusion weighted imaging (DWI) are advancing imaging technologies that have potential to overcome limitations of conventional staging methods, radiation treatment planning and the assessment of tumor response in esophageal or esophagogastric cancer. This study aimed to explore the value of MRI for the prediction of tumor response to chemoradiotherapy and accurate target volume delineation as compared to CT simulation for patients with unresectable or potentially resectable esophageal or esophagogastric cancer undergoing chemoradiotherapy. The average CT texture features are also extracted before and during treatment to establish a model to predict the prognosis or side effects (e.g. radiation pneumonitis or esophagitis) of patients.",[25,26],"2023-11-21",{"date":86,"type":35},"2023-11-24",{"date":88,"type":4},"2016-10",{"date":90,"type":19},"2026-12",{"name":41,"class":42},""]